Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Cardiol Therapeutics Inc.: Strengths and Weaknesses

  • The company has a poor ESG score according to MSCI, which ranks companies by sector.
Highlights: Cardiol Therapeutics Inc.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: Cardiol Therapeutics Inc.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

Cardiol Therapeutics Inc. SectorCanada

Fundamentals

-

Growth

Revenue growth

-

EPS growth

FCF growth

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

More ratings

Rating Valuation

Cardiol Therapeutics Inc. SectorCanada

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Cardiol Therapeutics Inc. SectorCanada

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Cardiol Therapeutics Inc. SectorCanada

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Cardiol Therapeutics Inc. SectorCanada

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
139M - - - -
47.88B
AAA
39.09B -
B
- -
36.75B -
40.55B
AAA
27.96B
A
16.77B - - - -
15.94B
BBB
13.55B
AA
13.81B
AAA
Average 25.24B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. CRDL Stock
  4. Ratings Cardiol Therapeutics Inc.